Bridgeway Capital Management LLC Sells 107,200 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN)

Bridgeway Capital Management LLC cut its position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 45.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 128,400 shares of the company's stock after selling 107,200 shares during the period. Bridgeway Capital Management LLC owned 0.23% of Design Therapeutics worth $792,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Dimensional Fund Advisors LP lifted its holdings in Design Therapeutics by 60.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 215,265 shares of the company's stock worth $1,328,000 after purchasing an additional 80,905 shares during the last quarter. Walleye Capital LLC raised its position in shares of Design Therapeutics by 101.6% in the fourth quarter. Walleye Capital LLC now owns 141,127 shares of the company's stock valued at $871,000 after purchasing an additional 71,127 shares during the period. Northern Trust Corp lifted its stake in shares of Design Therapeutics by 15.2% in the fourth quarter. Northern Trust Corp now owns 388,125 shares of the company's stock worth $2,395,000 after buying an additional 51,351 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Design Therapeutics by 119.3% during the 4th quarter. JPMorgan Chase & Co. now owns 89,215 shares of the company's stock worth $550,000 after buying an additional 48,528 shares during the period. Finally, XTX Topco Ltd bought a new stake in shares of Design Therapeutics during the 4th quarter worth $299,000. 56.64% of the stock is owned by hedge funds and other institutional investors.

Design Therapeutics Trading Up 4.5%

DSGN traded up $0.15 during trading on Friday, hitting $3.51. The stock had a trading volume of 70,352 shares, compared to its average volume of 187,548. The firm has a market cap of $199.26 million, a PE ratio of -4.13 and a beta of 1.77. Design Therapeutics, Inc. has a 12 month low of $2.60 and a 12 month high of $7.77. The company has a 50 day simple moving average of $3.88 and a 200-day simple moving average of $4.89.

Design Therapeutics (NASDAQ:DSGN - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.03). As a group, sell-side analysts anticipate that Design Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.